Celgene selling notes in three parts Thursday via four bookrunners

By Aleesia Forni

Virginia Beach, Va., Aug. 1 - Celgene Corp. is planning to sell senior notes in three parts on Thursday, according to a 424B3 filing with the Securities and Exchange Commission.

The notes will be sold in tranches due 2018, 2023 and 2043.

Barclays, Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are the joint bookrunners.

The company plans to use the proceeds for general corporate purposes, which may include further development of its clinical and pre-clinical programs, capital expenditures, general corporate development activities, meeting working capital needs, share repurchases of its common stock and repayment of some or all of its outstanding commercial paper.

Celgene is a Summit, N.J.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.